2022-11-10
Camurus' Interim Report for the third quarter, which was published today, showed that this was Camurus' financially best quarter to date.
Read the full press release on Camurus' website:
2020-06-24
Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…
Read more2020-06-23
The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…
Read more2020-05-07
”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read more2020-04-08
Camurus Annual Report for 2019 is now available at the company´s website.
Read more2020-04-03
Camurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal®…
Read more